title: Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
abstract: A randomized, double-blind, phase III trial of generic glatiramer acetate has shown equivalent efficacy and safety compared with the approved formulation, Copaxone. The impact of approval of generic glatiramer acetate, however, will mainly depend on the pricing of the drug.
authors.affiliation: Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
authors.forename: Per Soelberg
authors.initials: PS
authors.lastname: Sørensen
mesh_terms: D005260:Female; D000068717:Glatiramer Acetate / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D000068717:Glatiramer Acetate